CRT, Merck Serono Ink Deal For Drugs to Block WNT Signal

Moran, Nuala
August 2013
BioWorld International;8/7/2013, Vol. 18 Issue 32, p3
The article reports on the agreement between Cancer Research Technology Ltd. (CRT) and Germany's Merck Serono SA to develop compounds that block the WNT cell-signaling passageway. CRT's prior agreements include that of Forma Therapeutics Inc.'s to discover deubiquitinating enzymes and Astrazeneca plc's to co-explore inhibitors of unknown proteins associated with DNA damage reaction. It also discusses Merck Serono's rights to payment, milestones and royalty based on the agreement.


Related Articles

  • Alliances Update.  // PharmaWatch: Biotechnology;Sep2009, Vol. 8 Issue 9, p21 

    The article offers update related to collaborations on several biopharmaceutical companies. Amgen Inc. collaborated with GlaxoSmithKline to commercialize the monoclonal antibody denosumab of Amgen once the product is given approval. MSM Protein Technologies partnered with Merck Serono SA to...

  • Forma skips tech transfer brokers. Moran, Nuala // Nature Biotechnology;Sep2013, Vol. 31 Issue 9, p777 

    The article reports on the move of biopharmaceuticals company Forma Therapeutics Inc. to struck a deal with Cancer Research Technology (CRT) Ltd. and short circuit the process of technology transfer.

  • Ablynx Expands Merck Deal for Nanobody Technology. Moran, Nuala // BioWorld International;10/13/2010, Vol. 15 Issue 40, p1 

    The article reports that Ablynx NV has extended its deal with Merck Serono for nanobody antibody fragment technology. The deal will allow the application of the nanobody technology to an undisclosed rheumatology target. The terms of Ablynx's extended deal and its first agreement with Merck is...

  • Pharma: Other News To Note.  // BioWorld Today;5/16/2013, Vol. 24 Issue 94, p3 

    This section offers news briefs on the biotechnology industry including the clinical development agreement signed by Merck Serono SA and Quintiles Inc. and the approval received by Mylan Inc. for its Zolmitriptan Tablets for migraine.

  • Merck Serono spinouts. Orelli, Brian // Nature Biotechnology;Oct2012, Vol. 30 Issue 10, p907 

    The article informs that the company Merck Serono has outsourced its several research and development programs to the companies Prextron Therapeutics, and Quartz Bio and also reports that the funds worth of 30 million Euro have been invested in the Entrepreneur Partnership Program.

  • OTHER NEWS TO NOTE.  // BioWorld Today;2/26/2009, Vol. 20 Issue 37, p2 

    This section offers news briefs concerning the biotechnology industry. Ambrx Inc. has second partnership deal with Merck Serono, a division of Merck KGaA, for the development of Ambrx's preclinical multiple sclerosis drug ARX424. Ceragenix Pharmaceuticals Inc. has signed a distribution and...

  • Domain Inks $180M Early Stage GPCR Deal with Merck Serono. Moran, Nuala // BioWorld Today;1/19/2011, Vol. 22 Issue 12, p1 

    The article reports on the collaboration deal forged by Domain Therapeutics SA with Merck Serono SA for a discovery-stage program targeting a G protein-coupled receptor (GPCR) implicated in Parkinson's and other neurodegenerative diseases. It relates the amount of payment that Domain can receive...

  • Lpath in $473M Deal with Merck for Cancer Drug. Young, Donna // BioWorld Today;10/30/2008, Vol. 19 Issue 212, p1 

    The article reports that shares of Lpath Inc. rose 31 percent on October 29, 2008 on the news that the firm signed a deal with Merck Serono, a subsidiary of Merck KGaA, to develop an anticancer antibody that could potentially garner $473 million for Lpath. Under the agreement, Lpath will receive...

  • Merck and Ambrx expand collaboration to develop multiple sclerosis drug.  // PharmaWatch: CNS;Apr2009, Vol. 8 Issue 4, p7 

    The article reports on the announcement of Merck Serono SA and Ambrx Inc. for global business collaboration to develop and commercialize a drug for multiple sclerosis. Accordingly, the two will develop Ambrx's ARX424 preclinical product which was created through the use of Ambrx's proprietary...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics